DIC Pathophysiology: Why Clotting and Bleeding Coexist
Low fibrinogen is not required early in DIC: it can remain normal despite consumption. Fibrinolytic activity and laboratory patterns vary; no single D-dimer or fibrinogen result diagnoses or excludes the syndrome.Source
Why does DIC cause both clotting and bleeding?
Disseminated intravascular coagulation is an acquired systemic process in which coagulation activation, endothelial injury and dysregulated fibrinolysis can produce microthrombosis, bleeding and organ dysfunction. Platelets and clotting factors may be consumed while clots form. The clinical trigger and serial laboratory pattern matter more than any single abnormal result.
Key takeaways
- Thrombosis and bleeding can coexist through a systemic process.
- Normal fibrinogen does not exclude early or evolving DIC.
- An elevated D-dimer is not a stand-alone diagnosis.
How can clotting increase bleeding risk?
Systemic thrombin generation and fibrin deposition can contribute to microvascular thrombosis. At the same time, use of platelets and coagulation factors can impair effective hemostasis elsewhere. Endothelial injury and altered fibrinolysis add to the evolving pattern.
The balance varies between causes and phases. Do not assume that fibrinolysis is uniformly increased in every DIC phenotype or that every patient presents with the same combination of clotting and bleeding.
Why can fibrinogen still be normal?
Fibrinogen is also an acute-phase protein. Production during inflammation can offset consumption enough that a normal concentration remains possible. A normal early result therefore does not independently rule out the process.
Interpret the direction of change with platelet count, clotting times, fibrin-related markers and the underlying illness. A single high D-dimer is not specific enough to establish DIC.
What does the underlying trigger add?
The syndrome occurs in association with another illness, such as sepsis or major tissue injury. That context and the repeated clinical and laboratory assessment explain more than treating one number in isolation.
The 2025 ISTH update recognizes evolving phases and variable manifestations. This page covers mechanism and test interpretation rather than a transfusion or anticoagulation algorithm.
